Rivermark Medical Brings in $30M in Series C Funding

Rivermark Medical, a Milwaukee startup, has secured $30 million in Series C funding. The round was led by American Century Investments and included participation from Venture Investors Health Fund, Time BioVentures, and an unnamed strategic investor, with follow-on participation from existing investors View Ventures, Cadence Healthcare Ventures, and Anduril Investors LLC.

The clinical research startup plans to use the funds to continue their clinical development efforts, specifically for their flagship product – FloStent™ System. FloStent is a minimally invasive treatment option for Benign Prostatic Hyperplasia (BPH). With minimal invasion, a patient can have restored urinary function with a reduced recovery time.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts